A sensitive proximity ligation assay for active PSA

Biological Chemistry

Volumn 387, Issue 6, 2006, Pages 769-772

  Zhu, Lei ^a   Koistinen, Hannu ^a   Wu, Ping ^a   Närvänen, Ale ^b   Schallmeiner, Edith ^c   Fredriksson, Simon ^d   Landegren, Ulf ^c   Stenman, Ulf Håkan ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c UPPSALA UNIVERSITY   (Sweden)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immunoassay; Peptide; Prostate cancer; Prostate specific antigen

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN SPECIFICITY; CONFERENCE PAPER; CROSS REACTION; DIAGNOSTIC TEST; ENZYME ACTIVITY; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; IMMUNOASSAY; LIGATION; PHAGE DISPLAY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; PROTEIN DETERMINATION; SENSITIZATION;

ANTIBODY SPECIFICITY; HUMANS; IMMUNOASSAY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33745640748     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2006.096     Document Type: Conference Paper

References (23)

1. Armitage, T.G., Cooper, E.H., Newling, D.W., Robinson, M.R., and Appleyard, I. (1988). The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer. Br. J. Urol. 62, 584-589.
2. Catalona, W.J., Bartsch, G., Rittenhouse, H.G., Evans, C.L., Linton, H.J., Amirkhan, A., Horninger, W., Klocker, H., and Mikolajczyk, S.D. (2003). Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J. Urol. 170, 2181-2185.
3. Finne, P., Zhang, W.M., Auvinen, A., Leinonen, J., Maattanen, L., Rannikko, S., Tammela, T.L., and Stenman, U.H. (2000). Use of the complex between prostate specific antigen and α1-protease inhibitor for screening prostate cancer. J. Urol. 164, 1956-1960.
4. Fredriksson, S., Gullberg, M., Jarvius, J., Olsson, C., Pietras, K., Gustafsdottir, S.M., Ostman, A., and Landegren, U. (2002). Protein detection using proximity-dependent DNA ligation assays. Nat. Biotechnol. 20, 473-477.
5. Gullberg, M., Gustafsdottir, S.M., Schallmeiner, E., Jarvius, J., Bjarnegard, M., Betsholtz, C., Landegren, U., and Fredriksson, S. (2004). Cytokine detection by antibody-based proximity ligation. Proc. Natl. Acad. Sci. USA 101, 8420-8424.
6. Kumar, A., Mikolajczyk, S.D., Hill, T.M., Millar, L.S., and Saedi, M.S. (2000). Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen-induced LNCaP cells. Prostate 44, 248-254.
7. Leinonen, J., Zhang, W.M., Paus, E., and Stenman, U.H. (1999). Reactivity of 77 antibodies to prostate-specific antigen with isoenzymes and complexes of prostate-specific antigen. Tumour Biol. 20 (Suppl. 1), 28-34.
8. Leinonen, J., Wu, P., and Stenman, U.H. (2002). Epitope mapping of antibodies against prostate-specific antigen with use of peptide libraries. Clin. Chem. 48, 2208-2216.
9. Lilja, H., Christensson, A., Dahlen, U., Matikainen, M.T., Nilsson, O., Pettersson, K., and Lovgren, T. (1991). Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin. Clin. Chem. 37, 1618-1625.
10. Michel, S., Collomb-Clerc, E., Geourjon, C., Charrier, J.P., Passagot, J., Courty, Y., Deleage, G., and Jolivet-Reynaud, C. (2005). Selective recognition of enzymatically active prostate-specific antigen (PSA) by anti-PSA monoclonal antibodies. J. Mol. Recognit. 18, 225-235.
11. Mikolajczyk, S.D., Grauer, L.S., Millar, L.S., Hill, T.M., Kumar, A., Rittenhouse, H.G., Wolfert, R.L., and Saedi, M.S. (1997). A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 50, 710-714.
12. Mikolajczyk, S.D., Millar, L.S., Wang, T.J., Rittenhouse, H.G., Marks, L.S., Song, W., Wheeler, TM., and Slawin, K.M. (2000). A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res. 60, 756-759.
13. Mikolajczyk, S.D., Marker, K.M., Millar, L.S., Kumar, A., Saedi, M.S., Payne, J.K., Evans, C.L., Gasior, C.L., Linton, H.J., Carpenter, P., and Rittenhouse, H.G. (2001). A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 61, 6958-6963.
14. Niemela, P., Lovgren, J., Karp, M., Lilja, H., and Pettersson, K. (2002). Sensitive and specific enzymatic assay for the determination of precursor forms of prostate-specific antigen after an activation step. Clin. Chem. 48, 1257-1264.
15. Schedlich, L.J., Bennetts, B.H., and Morris, B.J. (1987). Primary structure of a human glandular kallikrein gene. DNA 6, 429-437.
16. Stamey, T.A., Yang, N., Hay, A.R., McNeal, J.E., Freiha, F.S., and Redwine, E. (1987). Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317, 909-916.
17. Stenman, U.H., Leinonen, J., Alfthan, H., Rannikko, S., Tuhkanen, K., and Alfthan, O. (1991). A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 51, 222-226.
18. Stenman, U.H., Paus, E., Allard, W.J., Andersson, I., Andres, C., Barnett, T.R., Becker, C., Belenky, A., Bellanger, L., Pellegrino, C.M., et al. (1999). Summary report of the TD-3 workshop: characterization of 83 antibodies against prostate-specific antigen. Tumour Biol. 20 (Suppl. 1), 1-12.
19. Vaisanen, V., Lovgren, J., Hellman, J., Piironen, T., Lilja, H., and Pettersson, K. (1999). Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells. Prostate Cancer Prostatic Dis. 2, 91-97.
20. Wu, P., Leinonen, J., Koivunen, E., Lankinen, H., and Stenman, U.H. (2000). Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. Eur. J. Biochem. 267, 6212-6220.
21. Wu, P., Zhu, L., Stenman, U.H., and Leinonen, J. (2004). Immunopeptidometric assay for enzymatically active prostate-specific antigen. Clin. Chem. 50, 125-129.
22. Zhang, W.M., Leinonen, J., Kalkkinen, N., Dowell, B., and Stenman, U.H. (1995). Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin. Chem. 41, 1567-1573.
23. Zhang, W.M., Finne, P., Leinonen, J., Salo, J., and Stenman, U.H. (2000). Determination of prostate-specific antigen complexed to α2-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. Urology 56, 267-272.